1. Home
  2. WOLF vs FULC Comparison

WOLF vs FULC Comparison

Compare WOLF & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wolfspeed Inc.

WOLF

Wolfspeed Inc.

HOLD

Current Price

$25.57

Market Cap

505.2M

Sector

Technology

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$7.17

Market Cap

535.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WOLF
FULC
Founded
1987
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
505.2M
535.5M
IPO Year
2025
2019

Fundamental Metrics

Financial Performance
Metric
WOLF
FULC
Price
$25.57
$7.17
Analyst Decision
Sell
Buy
Analyst Count
4
8
Target Price
$14.33
$16.38
AVG Volume (30 Days)
3.2M
925.3K
Earning Date
05-05-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,385,982,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.43
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.00
N/A
52 Week Low
$0.39
$3.78
52 Week High
$36.60
$15.74

Technical Indicators

Market Signals
Indicator
WOLF
FULC
Relative Strength Index (RSI) 55.13 41.03
Support Level $15.86 $6.39
Resistance Level $34.29 $8.26
Average True Range (ATR) 3.39 0.51
MACD 0.09 -0.03
Stochastic Oscillator 35.00 18.79

Price Performance

Historical Comparison
WOLF
FULC

About WOLF Wolfspeed Inc.

Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: